Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Evolus Inc (EOLS) today and set a price target of $35. The company’s shares opened today at $15.69.
Chen said:
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $35 for EOLS shares. We think DWP-450’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the recent approval of the potential upcoming U.S. approval of DWP-450 in early 2019, and the subsequent launches in spring 2019, should drive EOLS’s stock higher, in our view.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 16.3% and a 43.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Evolus Inc is a Strong Buy with an average price target of $29.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.50 and a one-year low of $6.75. Currently, Evolus Inc has an average volume of 358.9K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.
